title: Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice.
abstract: BACKGROUND
  Endothelin-1 participates in the pathophysiology of heart failure. The reasons for the lack of beneficial effect of endothelin antagonists in heart failure patients remain however speculative. The anti-apoptotic properties of ET-1 on cardiomyocytes could be a reasonable explanation. We therefore hypothesized that blocking the pro-apoptotic TNF-α pathway using pentoxifylline could prevent the deleterious effect of the lack of ET-1 in a model for heart failure.
  
  
  METHODS
  We performed transaortic constriction (TAC) in vascular endothelial cells specific ET-1 deficient (VEETKO) and wild type (WT) mice (n = 5-9) and treated them with pentoxifylline for twelve weeks.
  
  
  RESULTS
  TAC induced a cardiac hypertrophy in VEETKO and WT mice but a reduction of fractional shortening could be detected by echocardiography in VEETKO mice only. Cardiomyocyte diameter was significantly increased by TAC in VEETKO mice only. Pentoxifylline treatment prevented cardiac hypertrophy and reduction of fractional shortening in VEETKO mice but decreased fractional shortening in WT mice. Collagen deposition and number of apoptotic cells remained stable between the groups as did TNF-α, caspase-3 and caspase-8 messenger RNA expression levels. TAC surgery enhanced ANP, BNP and bcl2 expression. Pentoxifylline treatment reduced expression levels of BNP, bcl2 and bax.
  
  
  CONCLUSIONS
  Lack of endothelial ET-1 worsened the impact of TAC-induced pressure overload on cardiac function, indicating the crucial role of ET-1 for normal cardiac function under stress. Moreover, we put in light a TNF-α-independent beneficial effect of pentoxifylline in the VEETKO mice suggesting a therapeutic potential for pentoxifylline in a subpopulation of heart failure patients at higher risk.
authors: Department of Clinical Pharmacy, Kobe Pharmaceutical University, Kobe, Japan.
authors: Susi
authors: S
authors: Heiden
authors: Department of Clinical Pharmacy, Kobe Pharmaceutical University, Kobe, Japan.
authors: Nicolas
authors: N
authors: Vignon-Zellweger
authors: Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
authors: Shigeru
authors: S
authors: Masuda
authors: Department of Clinical Pharmacy, Kobe Pharmaceutical University, Kobe, Japan.
authors: Keiko
authors: K
authors: Yagi
authors: Department of Clinical Pharmacy, Kobe Pharmaceutical University, Kobe, Japan.
authors: Kazuhiko
authors: K
authors: Nakayama
authors: University of Texas Southwestern Medical Center, Howard Hughes Medical Institute, Dallas, United States of America.
authors: Masashi
authors: M
authors: Yanagisawa
authors: Department of Clinical Pharmacy, Kobe Pharmaceutical University, Kobe, Japan ; Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
authors: Noriaki
authors: N
authors: Emoto
mesh_terms: D000818:Animals; D001011:Aorta / Q000473:pathology; D017209:Apoptosis; D001794:Blood Pressure; D006332:Cardiomegaly / Q000235:genetics / Q000517:prevention & control; D004452:Echocardiography; D019332:Endothelin-1 / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000473:pathology*; D005260:Female; D020869:Gene Expression Profiling; D005838:Genotype; D006321:Heart / Q000502:physiology*; D006333:Heart Failure / Q000503:physiopathology*; D006339:Heart Rate; D051379:Mice; D018345:Mice, Knockout; D032383:Myocytes, Cardiac / Q000166:cytology; D010431:Pentoxifylline / Q000737:chemistry; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D019332:Endothelin-1; D014409:Tumor Necrosis Factor-alpha; D010431:Pentoxifylline